Phase 3 pivotal study of Epacadostat in Combination With Opdivo (nivolumab) in patients with first-line head and neck cancer

Trial Profile

Phase 3 pivotal study of Epacadostat in Combination With Opdivo (nivolumab) in patients with first-line head and neck cancer

Planning
Phase of Trial: Phase III

Latest Information Update: 04 May 2017

At a glance

  • Drugs Epacadostat (Primary) ; Nivolumab
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 May 2017 According to an Incyte Corporation media release, this trial is expected to initiate in 2017.
    • 07 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top